JPWO2020190768A5 - - Google Patents

Download PDF

Info

Publication number
JPWO2020190768A5
JPWO2020190768A5 JP2021555491A JP2021555491A JPWO2020190768A5 JP WO2020190768 A5 JPWO2020190768 A5 JP WO2020190768A5 JP 2021555491 A JP2021555491 A JP 2021555491A JP 2021555491 A JP2021555491 A JP 2021555491A JP WO2020190768 A5 JPWO2020190768 A5 JP WO2020190768A5
Authority
JP
Japan
Prior art keywords
dsrna
compound
oligonucleotide
independently
rna
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2021555491A
Other languages
English (en)
Japanese (ja)
Other versions
JP2022525208A (ja
Publication date
Application filed filed Critical
Priority claimed from PCT/US2020/022748 external-priority patent/WO2020190768A1/en
Publication of JP2022525208A publication Critical patent/JP2022525208A/ja
Publication of JPWO2020190768A5 publication Critical patent/JPWO2020190768A5/ja
Pending legal-status Critical Current

Links

JP2021555491A 2019-03-15 2020-03-13 組織特異的なapoe調節のためのオリゴヌクレオチド Pending JP2022525208A (ja)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US201962819189P 2019-03-15 2019-03-15
US62/819,189 2019-03-15
US201962864797P 2019-06-21 2019-06-21
US62/864,797 2019-06-21
US201962951441P 2019-12-20 2019-12-20
US62/951,441 2019-12-20
PCT/US2020/022748 WO2020190768A1 (en) 2019-03-15 2020-03-13 Oligonucleotides for tissue specific apoe modulation

Publications (2)

Publication Number Publication Date
JP2022525208A JP2022525208A (ja) 2022-05-11
JPWO2020190768A5 true JPWO2020190768A5 (sr) 2023-03-17

Family

ID=72520528

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2021555491A Pending JP2022525208A (ja) 2019-03-15 2020-03-13 組織特異的なapoe調節のためのオリゴヌクレオチド

Country Status (7)

Country Link
US (1) US20200362341A1 (sr)
EP (1) EP3937951A4 (sr)
JP (1) JP2022525208A (sr)
CN (1) CN113811311A (sr)
AU (1) AU2020239987A1 (sr)
CA (1) CA3133241A1 (sr)
WO (1) WO2020190768A1 (sr)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2021041247A1 (en) * 2019-08-23 2021-03-04 University Of Massachusetts O-methyl rich fully stabilized oligonucleotides
CN115955972A (zh) * 2020-04-27 2023-04-11 阿尔尼拉姆医药品有限公司 载脂蛋白E(APOE)iRNA剂组合物及其使用方法
CN114716518A (zh) * 2021-01-06 2022-07-08 圣诺制药公司 一种能够抑制pcsk9表达的分子构造及药物组合物
CA3223577A1 (en) * 2021-06-22 2022-12-29 University Of Massachusetts Oligonucleotides for ifn-.gamma. signaling pathway modulation
WO2023086777A1 (en) * 2021-11-09 2023-05-19 Children's National Medical Center Targeting apoe enhances t-cell killing in cancer immunotherapy
WO2024073705A1 (en) * 2022-09-30 2024-04-04 University Of Massachusetts Ocular delivery of oligonucleotides

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2006507841A (ja) * 2002-11-14 2006-03-09 ダーマコン, インコーポレイテッド 機能的siRNAおよび超機能的siRNA
US20060257851A1 (en) * 2002-11-26 2006-11-16 Itzhak Bentwich Bioinformatically detectable group of novel viral regulatory genes and uses thereof
EP1989307B1 (en) * 2006-02-08 2012-08-08 Quark Pharmaceuticals, Inc. NOVEL TANDEM siRNAS
EP2293800B1 (en) * 2008-06-06 2016-10-05 Quark Pharmaceuticals, Inc. Compositions and methods for treatment of ear disorders
CN106237345A (zh) * 2009-05-06 2016-12-21 库尔纳公司 通过针对脂质转运和代谢基因的天然反义转录物的抑制治疗脂质转运和代谢基因相关疾病
EP2960333B1 (en) * 2009-08-27 2017-10-04 Idera Pharmaceuticals, Inc. Composition for inhibiting gene expression and uses thereof
US20150141320A1 (en) * 2012-05-16 2015-05-21 Rana Therapeutics, Inc. Compositions and methods for modulating gene expression
US20150337030A1 (en) * 2012-05-31 2015-11-26 The Trustees Of Columbia University In The City Of New York Methods to treat alzheimer's disease using apoe inhibitors
US20170334977A1 (en) * 2014-10-20 2017-11-23 The Brigham And Women's Hospital, Inc. Targeting Apolipoprotein E (APOE) in Neurologic Disease
WO2017132669A1 (en) * 2016-01-31 2017-08-03 University Of Massachusetts Branched oligonucleotides
WO2021133941A1 (en) * 2019-12-23 2021-07-01 University Of Massachusetts Oligonucleotides for tissue specific gene expression modulation

Similar Documents

Publication Publication Date Title
US10538763B2 (en) Compounds and methods for modulation of DUX4
JP2018516091A5 (sr)
JP2019214587A5 (sr)
CN106983768B (zh) 用于在对象中调节smn2剪接的组合物和方法
CA2866392C (en) Methods for modulating tau expression for reducing seizure and modifying a neurodegenerative syndrome
KR20080031164A (ko) SR 단백질의 결합의 방해에 의해 그리고 이차 RNA구조의 방해에 의한 pre-mRNA에서 엑손 인식의조절
JP2023539341A (ja) Dux4阻害剤およびその使用方法
JP2022518929A (ja) Appの発現を低減するための化合物及び方法
JPWO2019181946A1 (ja) 毒性が軽減した核酸
JP2022188237A (ja) 転写プロセシングの調節のための化合物及び方法
JPWO2020190768A5 (sr)
WO2021157730A1 (ja) 核酸医薬とその使用
JP6934695B2 (ja) 核酸医薬とその使用
JPWO2020033899A5 (sr)
JPWO2020205605A5 (sr)
JPWO2020041769A5 (sr)
JPWO2021195307A5 (sr)
CA3132388A1 (en) Compositions and methods for treating huntington's disease
JPWO2021216556A5 (sr)
WO2022250050A1 (ja) scpBNA又はAmNAを含むヘテロ核酸
WO2023042876A1 (ja) 2'-修飾ヌクレオシドを含むヘテロ核酸
WO2023022229A1 (ja) モルホリノ核酸を含む修飾ヘテロ核酸
JP7208911B2 (ja) 核酸分子発現の調節
WO2021070959A1 (ja) 修飾ヘテロ核酸
Riasi et al. Gene silencing method based on DNA